Pharmacist Adriana Slana, registration number 2223315, was warned by the General Pharmaceutical Council (GPhC) after an inspection revealed “serious governance and systems failures” at the pharmacy she worked at.
At hearing on June 24, the GPhC’s investigating committee heard that the failures occurred between January and May 2024, while Slana was a superintendent pharmacist.
Read more: Pharmacist suspended for suppling Xanax ‘to overseas charities’
According to the determination document, the inspection identified drugs being supplied “without valid prescriptions”, inadequate record-keeping and medicines compounded “without appropriate supervision and without ingredients sourced from approved UK suppliers”.
“As a result, the pharmacy was placed under restrictive conditions,” it said.
“Lack of sufficient oversight”
The GPhC noted that as superintendent pharmacist of the pharmacy, Slana was responsible for its “overall governance and safe operation”.
It added that her “attendance at the pharmacy was limited” - and that while she did identify and raise concerns with management, she “failed to take further appropriate action when those concerns were not addressed”.
Read more: Pharmacy tech suspended over undisclosed assault conviction
“This demonstrated a lack of sufficient oversight expected of a superintendent pharmacist,” the regulator said.
The committee found that Slana had breached the GPhC’s standards on using professional judgement, demonstrating leadership and speaking up when one has concerns or things go wrong.
And it concluded that a warning was “the appropriate outcome in this case”.
Read more: Pharmacist warned after failing to record 300 flu vaccines
The regulator cautioned Slana that she “must ensure effective governance arrangements are in place” and “actively assure herself that a pharmacy is operating safely and lawfully”.
“Where serious concerns are identified and not remedied, she must take appropriate and timely action,” it added.
“Any similar conduct will be likely to result in further regulatory intervention.”
Read more: ‘Lacking integrity’: Pharmacist accessed competitor’s patient data
The warning will be published on the register and available for 12 months.
Read the determination in full here.
